Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HBHOPE is a hematinic combination product developed and marketed by Medisun Lifescience. It is formulated as a syrup and is primarily indicated for the treatment and prevention of iron-deficiency anemia and associated nutritional deficiencies. The formulation typically contains ferric ammonium citrate as a source of iron, folic acid (Vitamin B9) to support DNA synthesis and erythropoiesis, and cyanocobalamin (Vitamin B12) for proper red blood cell maturation and neurological function. As a branded generic product, it is used to replenish iron stores and improve hemoglobin levels in patients with nutritional anemia or increased physiological demands, such as during pregnancy or recovery from illness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ferric ammonium citrate + folic acid + cyanocobalamin.